Other News To Note
Thursday, June 9, 2011
Morphotek Inc., of Exton, Pa., a subsidiary of Eisai Inc., said the FDA granted orphan designation to two of its cancer drugs, MORAb-004 in soft-tissue sarcoma and MORAb-066 in pancreatic cancer. Orphan designation will guarantee seven years of marketing exclusivity upon approval. MORAb-004, a humanized monoclonal antibody to endosialin/tumor endothelial marker-1, is in a Phase I study, while MORAb-066, a humanized monoclonal antibody to tissue factor, is in preclinical testing.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.